Trending stocks today
Evome Medical Technologies (EVMT-X)
CVE:EVMT
0.12
0.02
(14.29%) 1d
Financials
Technical Analysis
This summary was created by AI, based on 1 opinions in the last 12 months.
Evome Medical Technologies, formerly Salona Global Medical, has undergone a shift in management and strategy to address concerns about acquisition debt. The company is focusing on paying down debt and leveraging new technology to drive revenue growth. With a goal to eliminate acquisition debt by late 2024/early 2025, Evome is also looking for opportunities outside of North America. The market has been largely unaware of these positive developments, as the company remains under the radar.
N/A
Unknown
- «
- ‹
- 1
- ›
- »
Evome Medical Technologies(EVMT-X) Rating
Ranking : 1 out of 5
Bullish - Buy Signals / Votes : 0
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 0
Evome Medical Technologies(EVMT-X) Frequently Asked Questions
What is Evome Medical Technologies stock symbol?
Evome Medical Technologies is a Canadian stock, trading under the symbol EVMT-X on the TSX Venture Exchange (EVMT-CV). It is usually referred to as TSXV:EVMT or EVMT-X
Is Evome Medical Technologies a buy or a sell?
In the last year, there was no coverage of Evome Medical Technologies published on Stockchase.
Is Evome Medical Technologies a good investment or a top pick?
Evome Medical Technologies was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Evome Medical Technologies.
Why is Evome Medical Technologies stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Evome Medical Technologies worth watching?
In the last year, there was no coverage of Evome Medical Technologies published on Stockchase.
What is Evome Medical Technologies stock price?
On 2025-01-17, Evome Medical Technologies (EVMT-X) stock closed at a price of $0.12.
(Formerly Salona Global Medical, SGMD-X)
Acquisition strategy in physiotherapy, racked up a fair bit of debt. Market got concerned. New management, paying down some debt by selling off divisions. Goal is to get rid of all acquisition debt by late 2024/early 2025. New tech has made equipment smaller and more technology-driven, which will allow for mass sales.
Revenue ramping up, EBITDA has turned positive. Under the radar. Looking to do deals outside NA as well.